Syntach AB announces €17.5M in Blended Funding, Names Patrick NJ Schnegelsberg as New CEO, and Appoints Cansel Isikli as VP of RA/Q
LUND, Sweden, Jan. 30, 2023 /PRNewswire/ - Swedish medtech startup Syntach AB has been awarded up to €15 million in equity financing by European Innovation Council (EIC) for the development of the Syntach Cardiac Support System, a breakthrough device for patients with heart failure. This approval follows the award of a €2.5...
Stemline Therapeutics, a subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDUTM (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+,...
ESR1 mutations are present in up to 40% of ER+, HER2- advanced or metastatic breast cancers. ESR1 mutations are a known driver of resistance to standard endocrine therapy, and so far, have been difficult to treat. ORSERDU is the first endocrine innovation in more than 20 years, specifically addressing ESR1 mutations,...
Duoning Headquarters in Fengxian Biotechnology Park with Centers for R&D and Technology Applications
SHANGHAI, Jan. 30, 2023 /PRNewswire/ -- Shanghai Duoning Biotechnology Co., Ltd. ("Duoning") announced that the company signed an Agreement on the Transfer of the Right to Use State-owned Construction Land with the Bureau of Planning and Natural Resources of Fengxian District, Shanghai and officially settled its global headquarters in the Biotechnology Park of Shanghai Fengxian Economic Development Zone. And Duoning will...
Chula Medicine Reveals Detection of Latent Dementia
Thai Red Cross Emerging Infectious Diseases Health Science Center, Faculty of Medicine, Chulalongkorn University has researched a blood test for markers of Alzheimer's that can give a 10-year warning, so people can be prepared to slow down the development of dementia in old age. BANGKOK, Jan. 30, 2023 /PRNewswire/ -- Poosanu Thanapornsangsuth, M.D., lecturer of Neurology, the Department of Internal...
Abbisko Therapeutics announces that US FDA has granted breakthrough therapy designation for its CSF-1R inhibitor Pimicotinib（ABSK021）
SHANGHAI, Jan. 30, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) today announced that its CSF-1R inhibitor Pimicotinib（ABSK021）has been granted the breakthrough therapy designation from FDA for the treatment of tenosynovial giant cell tumor (TGCT) patients that are not amenable to surgery. This breakthrough therapy designation approval is based on results from the phase Ib clinical trial...
Alpha Biopharma Submits New Drug Application for Zorifertinib, a Next-Generation EGFR-TKI to Treat EGFR-mutated NSCLC Patients with CNS Metastases
SHANGHAI, Jan. 30, 2023 /PRNewswire/ -- Alpha Biopharma, a developer of innovative drugs, announces that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for Zorifertinib, a next-generation EGFR-TKI specially designed to treat advanced EGFR-mutated non-small cell lung cancer (NSCLC) patients with central nervous system (CNS) metastases. Zorifertinib...
PanopticAI Secures Fundraising Co-Led by Alibaba Hong Kong Entrepreneurs Fund and Gobi Partners GBA to Digitise Remote Healthcare
HONG KONG, Jan. 30, 2023 /PRNewswire/ -- PanopticAI, Hong Kong's leading health and wellness monitoring startup, announced a deal closing on a seed-round funding co-led by Alibaba Hong Kong Entrepreneurs Fund (AEF) and Gobi Partners GBA (Gobi GBA), with participation from the HKUST Entrepreneurship Fund (E-Fund) and other renowned investors, marking a promising move in the digital healthcare industry....
WHO Goodwill Ambassador for Leprosy Elimination Has Audience with Pope Francis
Pope Supports Continued Efforts Against Leprosy, Reflects on Tragedy of War TOKYO, Jan. 27, 2023 /PRNewswire/ -- WHO Goodwill Ambassador for Leprosy Elimination Yohei Sasakawa had an audience with His Holiness Pope Francis at the Vatican on January 26, 2023, during which he requested the Pope's support in eliminating leprosy and the prejudice and discrimination associated with the disease....
SK bioscience Introduces New Partnership Model to Establish Regional Vaccine Hubs
SK bioscience shared a development history of the South Korea's first COVID-19 vaccine at the Riyadh Global Medical Biotechnology Summit 2023 (RGBMS 2023) in the Kingdom of Saudi Arabia(KSA) SK bioscience also explained a new global partnership model aiming to promote public health in developing countries SEOUL, South Korea, Jan....
Samsung Biologics Reports Fourth Quarter & Fiscal Year 2022 Financial Results
Q4'22 consolidated revenue of KRW 965.5 billion and Q4'22 operating profit of KRW 312.8 billion. FY'22 consolidated revenue of KRW 3.00 trillion and FY'22 operating profit of KRW 983.6 billion. Strong growth momentum expected to continue with active expansions in capacity, geography, and portfolio. INCHEON, South Korea, Jan. 27, 2023 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's...
